Contraindications: Testosterone Enanthate is contraindicated in individuals with androgen-dependent prostate carcinoma or breast carcinoma, existing polycythaemia, untreated sleep apnoea, or known hypersensitivity to any component of the formulation. Women who are pregnant or may become pregnant must not use this product.
Side_Effects: Supraphysiological testosterone exposure during bulking phases elevates aromatisation rate, increasing oestradiol load and the associated risks of water retention, blood pressure elevation, and gynaecomastia. Androgenic effects including acne, accelerated scalp hair thinning, and sebaceous gland overactivity are dose-dependent and more pronounced during high-calorie bulk phases. Erythrocytosis — elevated red blood cell mass — should be anticipated in cycles exceeding twelve weeks at doses above 400 mg/week.
Monitoring: Obtain a full hormone panel (total testosterone, free testosterone, oestradiol, LH, FSH), haematocrit, haemoglobin, lipid panel, and liver enzymes at baseline before the cycle begins. Repeat bloodwork at weeks four and eight during the bulk. Haematocrit values approaching 50% warrant immediate dose review; values exceeding 52% require medical consultation and possible therapeutic intervention.
PCT: Post-cycle therapy with a selective oestrogen receptor modulator — Nolvadex (tamoxifen) at 20–40 mg/day or Clomid (clomiphene) at 50 mg/day — should begin approximately fourteen days after the final Testo Depot injection, once declining serum testosterone permits HPTA signalling recovery. PCT duration is typically four weeks following a standard bulking cycle and may extend to six weeks after cycles longer than fourteen weeks.